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Letters e135There are reports of NTM infections being
contracted after tattooing3,4 and acupuncture.5
However, to our knowledge, this is the first reported
case of M fortuitum infection associated with AET.
Thus, practitioners should suspect mycobacterial
infection in patients presenting with nodules and
abscesses in areas that have been treated with AET.
Such infections should be treated promptly to
minimize further disfigurement.
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concomitant vemurafenib therapy in a patient
with metastatic melanoma
To the Editor: A 31-year-old woman was diagnosed
with a nonulcerated 2.01-mm deepmelanoma on her
left arm. She underwent wide excision with negative
surgical margins and a negative sentinel lymph node
biopsy. Sevenmonths later, she started having left hip
pain that became progressively worse. A noncontrastmagnetic resonance image revealed a large lesion in
her left proximal femur that was subsequently bio-
psied, confirming the diagnosis of metastatic mela-
noma. Subcutaneous lesions on her trunk and thighs
also developed. Biopsies revealed melanoma with
positive BRAF V600E mutation. She was started on
vemurafenib, a selective BRAF V600E inhibitor,1
dosed at 960 mg twice daily. After 3 weeks of
vemurafenib, she began receiving localized radio-
therapy to treat her femoral lesion. After 1 week of
daily radiotherapy, a brisk, raised, erythematous skin
reaction restricted to her left anterior and posterior
thigh developed. The erythematous regions were
confined to the areas where she was receiving
radiotherapy. With continuation of radiotherapy for
3 more days, an acute, rapidly worsening, and
extremely painful burning sensation developed in
her left anterior and posterior thigh. Physical exam-
ination revealed blistered and erythematous skinwith
dry andmoist desquamation in the radiotherapy fields
on her left anterior and posterior thigh, indicative of a
worsening skin reaction consistent with radiation
burns. She had received a total radiation dose of 30
Gy in 10 uninterrupted daily 3-Gy fractions as
originally planned. With discontinuation of radio-
therapy, her radiationdermatitis healed after 1month.
Two cases of localized radiation dermatitis that
resolved with topical corticosteroids and did not
require cessation of vemurafenib have been reported
in patients who started vemurafenib after completion
of radiotherapy.2 Another case of radiodermatitis was
reported in a patient receiving concomitant vemur-
afenib and radiotherapy who had been earlier
administered 60 Gy of local radiotherapy to the
same area that 4.5 years later developed radioderma-
titis upon administration of 20 Gy of radiotherapy.3
To our knowledge, our case represents the first
reported instance in the English literature of localized
radiation dermatitis developing in a patient receiving
concomitant vemurafenib and radiotherapy whowas
previously naive to both treatment modalities.
Sustained erythema seen in radiation dermatitis
typicallymanifests 10 to 14 days after dosing,whereas
sustained erythema developed in our patient after 7
days of radiotherapy. Moreover, the severity of the
radiation dermatitis seen in our patient after 10 days
of radiotherapy is not usually seen until after 4 to 5
weeks of radiotherapy at doses of 40 Gy or greater.
The radiosensitizing effect of vemurafenib leads to
increased cellular damage and impaired DNA repair.4
One proposed mechanism for radiosensitization sec-
ondary to vemurafenib suggests that vemurafenib
activates wild-type BRAF in keratinocytes and leads
to radiosensitization as a result.3 However, the exact
mechanism remains unclear. Dermatologists should
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with vemurafenib administration and carefully
monitor patients receiving concomitant radiotherapy,
as well as patients who start vemurafenib after
radiotherapy. Neither radiotherapy nor vemurafenib
need be stopped if radiation dermatitis develops, in
that reported cases resolved without further adverse
events after topical corticosteroid administration,
cessation of radiotherapy, or both.
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Treatment of epidermolysis bullosa
pruriginosa using systemic and topical agents
To the Editor: A 46-year-old Hispanic woman pre-
sented to our dermatology clinic with a 6-year history
of an intermittent pruritic vesicobullous eruption on
her lower legs and, to a lesser extent, on her forearms
(Fig 1, A). She had failed to respond to prior
treatments, including topical and intralesional corti-
costeroids, mycophenolate mofetil, and photother-
apy. There was no family history of a similar
condition. Histologic findings showed subepidermal
clefts with minimal inflammation. Direct immuno-
fluorescence on perilesional skin was negative. A
complete workup for immunobullous disease and
porphyria was negative. Electron microscopy
demonstrated separation of the sublamina densa
with a reduced number of anchoring fibrils, whichwas clinically consistent with dystrophic epidermol-
ysis bullosa pruriginosa (EBP). DNA extraction from
peripheral blood followed by bidirectional COL7A1
gene sequencing (GeneDx, Gaithersburg, MD) re-
vealed a novel compound heterozygotic mutation; a
guanine (G) to cytosine (C) splice site mutation at the
beginning of intron 51 (IVS5111 G/C) and adenine
(A) to thymine (T) resulting in a codon mutation of
glutamine (Gln) to leucine (Leu) at position 1924
( p.Gln1924Leu) on exon 69.
Pruritus and excoriation are critical in unmasking
skin fragility in EBP. Given the pauci-inflammatory
nature of EBP, we focused on the control of pruritus
with the use of ketamine 0.5% and amitriptyline 2%
(KA) topical gel. With regular use of KA gel, the
patient described a 90% decrease in localized pruri-
tus and blistering. Subsequently, the patient was
started on sertraline for depressive symptoms. Over
the 6-month period on oral sertraline and KA gel,
the patient had virtually complete resolution of
localized and generalized pruritus with minor
relapses (Fig 1, B).
Effective treatment of EBP is challenging, and
long-term outcomes are rarely described in the
literature. Treatments reported to date include corti-
costeroids, antihistamines, cryotherapy, tacrolimus,
cyclosporine, and thalidomide.1 However, control of
inflammation has not demonstrated consistent effi-
cacy. Based on the structural fragility of EBP,
unmasked by severe pruritus and scratching, we
advocate focusing the treatment on the control of
pruritus, minimizing trauma, and managing lower
extremity edema. Topical KA is thought to act pre-
and post-axonally in the transmission of pain and
possibly pruritus. Poterucha et al2 showed that
topical KA had a 62% response rate in a wide variety
of cutaneous disorders, without inducing systemic
side effects.2,3 Interestingly, the concomitant use of
sertraline for mild depressive symptoms further
improved the patient’s generalized pruritus and
EBP. Sertraline has been reported as a first-line
treatment for cholestatic pruritus and implicates
serotonergic mediators in the pruritus of EBP.4 The
exact mechanism of action is unknown but is
thought to have a regulatory action on the trans-
mission of itch signals.5
The efficacy and minimal medication risk with
the combined oral and topical therapies reported
here favor this approach as a primary treatment of
EBP, a disease that necessitates long-term manage-
ment. Additional studies are required to further
validate the efficacy of systemic sertraline and
topical KA for treatment of EBP and possibly other
skin conditions in which pruritus plays a key
pathogenic role.
